多靶点药物研究新技术及其应用进展

神经药理学报››2011,Vol. 1››Issue (4): 48-54.

多靶点药物研究新技术及其应用进展

刘少强^1，²，铁璐¹，李学军¹

1. 北京大学基础医学院药理学系，北京，100191，中国
2. 北京大学第三医院，北京，100191，中国

出版日期:2011-08-26发布日期:2012-11-24
通讯作者:李学军，女，教授，博士生导师；研究方向：水通道的生物学研究和新药发现，药物蛋白质组学和药物靶点的发现和确认；Tel：+86-010-82802863，E-mail：xjli@bjmu.edu.cn
作者简介:刘少强，男，北京大学临床医学八年制本博连读生；E-mail：shaoqiangliu@pku.edu.cn
基金资助:

国家自然科学基金项目（No.91129727、81020108031、30973558、30572202、30901815、30901803），国家基础科学人才培养基金项目（No.J1030831/J0108）

Application Advances on Novel Techniques in Multi-target Drugs Discovery

LIU Shao-qiang¹^，2，TIE Lu¹，LI Xue-jun¹

1. Department of Pharmacology，School of Basic Medical Sciences，Peking University，Beijing，100191，China
2. Peking University Third Hospital， Beijing，100191，China

Online:2011-08-26Published:2012-11-24

摘要/Abstract

摘要：在药物研发领域，从“单药单靶点”向基于系统生物学理论的“多靶点药物”转变已成为必然趋势。从多角度攻击疾病系统，同时调节疾病网络系统的多个环节，可以克服许多单靶点药物的局限性，并且不易产生抗药性。虽然多靶点药物现已开始应用于很多重大疾病的治疗，但其研究仍然面临众多挑战，需要开拓和完善药物研究的新技术。本文综述了多靶点药物研究新技术的最新研究进展，介绍多靶点miRNA反义核苷酸技术、表面等离子共振技术、多维液相色谱-质谱联用技术等新技术在多靶点药物研究中的应用，并展望多靶点药物研究技术未来的发展方向，对多靶点药物发现具有重要意义。

关键词:多靶点药物,多维液相色谱-质谱联用技术,表面等离子共振技术,多靶点miRNA反义核苷酸技术

Abstract:Compared with drugs designed to act against individual molecular targets，multi-target drugs that impact multiple targets simultaneously are better at controlling complex disease systems and are less prone to drug resistance. However，how to design multi-target drugs presents a great challenge. With the rapid progress in multi-target drugs research，some novel techniques in laboratories have emerged and are very likely to be effectively applied in combating multigenic diseases or diseases that affect multiple tissues. This review deals with the recent progress in multi-target drugs research，some novel techniques and their applications in drug discovery.

Key words:multi-target drugs,multi-target anti-miRNA antisense oligonucleotides technology,surface plasmon resonance technology,multidimensional liquid chromatography/mass spectrometry

中图分类号:

R91
R9-39

刘少强，铁璐，李学军. 多靶点药物研究新技术及其应用进展[J]. 神经药理学报, 2011, 1(4): 48-54.

LIU Shao-qiang，TIE Lu，LI Xue-jun. Application Advances on Novel Techniques in Multi-target Drugs Discovery[J]. Acta Neuropharmacologica, 2011, 1(4): 48-54.

参考文献

1 Grant R Zimmermann, Joseph Lehar, Curtis T Keith. Multi-target therapeutics: when the whole is greater than the sum of the parts[J]. Drug Discov Today, 2007, 12(1-2):34-42.

2 Peter Csermely, Vilmos Agoston, Sandor Pongor. The efficiency of multi-target drugs: the network approach might help drug design[J]. Trends Pharmacol Sci, 2005, 26(4):178-182.

3 Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases[J]. Expert Rev Clin Pharmacol,2011, 4(3):293-298.

4 Bajda M, Guzior N, Ignasik M, et al. Multi-target-directed ligands in Alzheimer's disease treatment[J]. Curr Med Chem, 2011, 18(32):4949-4975.

5 Min-Hee Pang, Yuntae Kim, Kyung Woon Jung, et al. A series of case studies: practical methodology for identifying antinociceptive multi-target drugs[J]. Drug Discov Today, 2012,17(9-10):425-434.

6 Ohlson S. Designing transient binding drugs: a new concept for drug discovery[J]. Drug Discov Today, 2008, 13(9-10):433-439.

7 Richard Morphy, Corinne Kay, Zoran Rankovic. From magic bullets to designed multiple ligands[J]. Drug Discovery Today, 2004, 9(15):641-651.

8 Louis M Tsai, Di Yu. MicroRNAs in common diseases and potential therapeutic applications[J]. Clin Exp Pharmacol Physiol, 2010, 37(1):102-107.

9 Ranjan J Perera, Animesh Ray. MicroRNAs in the search for understanding human diseases[J]. Bio drugs, 2007, 21(2):97-104.

10 Boutla A, Delidakis C, Tabler M. Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identi?cation of putative target genes[J]. Nucleic Acids Res, 2003, 31(17):4973-4980.

11 Gayathri R Devi, Tomasz M Beer, Christopher L Corless, et al. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors[J]. Clin Cancer Res, 2005, 11(10):3930-3938.

12 Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides[J]. Gene Ther, 2011, 18(12):1111-1120.

13 Lu Y, Xiao J, Lin H, et al. Complex antisense inhibitors offer a superior approach for microRNA research and therapy[J]. Nucleic Acids Res, 2009, 37:e24-e33.

14 Thomas Thum, Paolo Galuppo, Christian Wolf, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure[J]. Circulation, 2007, 116(3):258-267.

15 Stefano Volinia, George A Calin, Liu Changgong, et al. A microRNA expression signature of human solid tumors defines cancer gene targets[J]. Proc Natl Acad Sci U S A, 2006, 103(7):2257-2261.

16 Meng Qingwen, Zhang Zaiping, Wang Wen, et al. Enhanced inhibition of Avian leukosis virus subgroup J replication by multi-target miRNAs[J]. Virol J, 2011, 8(1):556.

17 Pranavan Thillaivinayagalingam, Julien Gommeaux, Michael McLoughlin, et al. Biopharmaceutical production: Applications of surface plasmon resonance biosensors[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2010, 878(2):149-153.

18 Visser NF, Heck AJ. Surface plasmon resonance mass spectrometry in proteomics[J]. Expert Rev Proteomics, 2008, 5(3):425-433.

19 Jacquemart R, Chavane N, Durocher Y, et al. At-line monitoring of bioreactor protein production by Surface Plasmon Resonance[J]. Biotechnol Bioeng, 2008, 100(1):184-188.

20 Bader B, Kuhn K, Owen DJ, et al. Bioorganic synthesis of lipid-modified proteins for the study of signal transduction[J]. Nature, 2000, 403(6766):223-226.

21 Anthony M Giannetti, Bruce D Koch, Michelle F Browner. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors[J]. J Med Chem, 2008, 51(3):574-580.

22 Navratilova I, Hopkins AL. Emerging role of surface plasmon resonance in fragment-based drug discovery[J]. Future Med Chem, 2011, 3(14):1809-1820.

23 Heim-Riether A, Taylor SJ, Liang S, et al. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors[J]. Bioorg Med Chem Lett, 2009, 19(18):5321-5324.

24 Neumann T, Junker HD, Schmidt K, et al. SPR-based fragment screening: advantages and applications[J]. Curr Top Med Chem, 2007, 7(16):1630-1642.

25 Stephen S Antonysamy, Brandon Aubol, Jeff Blaney, et al. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors[J]. Bioorg Med Chem Lett, 2008, 18(9):2990-2995.

26 Baty JW, Hampton MB, Winterbourn CC. Detection of oxidant sensitive thiol proteins by fluorescence labeling and two-dimensional electrophoresis[J]. Proteomics, 2002, 2(9):1261-1266.

27 Wang Hong, Hanash S. Multi-dimensional liquid phase based separations in proteomics[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 787(1):11-18.

28 Bilello JA. The agony and ecstasy of "OMIC" technologies in drug development[J]. Current Mol Med, 2005, 5(1):39-52.

29 Zhang Xiang, Fang Aiqin, Catherine P Riley, et al. Multi-dimensional liquid chromatography in proteomics-A review[J]. Anal Chim Acta, 2010, 664(2):101-113.

30 Scott W Simpkins, Jeremy W Bedard, Stephen R Groskreutz, et al. Targeted three-dimensional liquid chromatography: a versatile tool for quantitative trace analysis in complex matrices[J]. J Chromatogr A, 2010, 1217(49):7648-7660.

31 Gao M, Qi D, Zhang P, et al. Development of multidimensional liquid chromatography and application in proteomic analysis[J]. Expert Rev Proteomics, 2010, 7(5):665-678.

32 Baynham MT, Patel S, Moaddel R, et al. Multidimensional on-line screening for ligands to the alpha3beta4 neuronal nicotinic acetylcholine receptor using an immobilized nicotinic receptor liquid chromatographic stationary phase[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 772(1):155-161.

33 Dai Jie, Jin Wenhai, Sheng Quanhu, et al. Protein phosphorylation and expression profiling by Yin-Yang multidimensional liquid chromatography (Yin-Yang MDLC) mass spectrometry[J]. J Proteome Res, 2007, 6(1):250-262.

34 Hao P, Qian J, Dutta B, et al. Enhanced Separation and Characterization of Deamidated Peptides with RP-ERLIC-Based Multidimensional Chromatography Coupled with Tandem Mass Spectrometry[J]. J Proteome Res, 2012,11(3):1804-1811.

35 Martin Vollmer, Edgar Nägele, Patric Hörth. Differential Proteome Analysis: Two-Dimensional Nano-LC/MS of E.Coli Proteome Grown on Different Carbon Sources[J]. J Biomol Tech, 2003, 14(2):128-135.

36 Jae Hong Kim, Ji Hyun Yeom, Jeong Jae Ko, et al. Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles[J]. J Biotechnol, 2011, 155(3):287-292.

37 Yoshida M, Loo JA, Lepley RA. Proteomics as a tool in the pharmaceutical drug design process[J]. Curr Pharm Des, 2001, 7(4):291-310.